Cumberland Pharmaceuticals Pitch Deck

Strategic Review 5 In early 2019, we initiated a strategic review of our products, partners and organization to ensure we have the proper focus and capabilities. As a result: • We extended the arrangement with Clinigen to continue to promote Ethyol and Totect until the end of the year. We have concluded our co-promotion arrangement with Pirimal Critical Care. A transition plan has been implemented to transition Caldolor and Vaprisol accounts from Piramal to Cumberland. We finalized Vibativ agreements with SciClone for China and Dr. Reddy's Laboratories for India.

View entire presentation